Intravitreal bevacizumab for choroidal neovascularization secondary to Vogt-Koyanagi-Harada syndrome

Wu, Lihteh; Evans, Teodoro; Saravia, Mario; Schlaen, Ariel; Couto, Cristóbal

doi:10.1007/s10384-008-0600-4

Cited by 37 publications

(18 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Intravitreal injections of anti-VEGF have been used successfully for the treatment of CNVs,155 and combined treatment of triamcinolone acetate and anti-VEGF has also been tried to treat recurrent CNVs 156. Persistent SRDs involving the fovea in four patients with bilateral VKHD were successfully resolved using intravitreal injections of anti-VEGF 142…”

Section: Historical Aspects and Epidemiologymentioning

confidence: 99%

Vogt–Koyanagi–Harada syndrome – current perspectives

Baltmr¹,

Lightman²,

Tomkins-Netzer³

2016

OPTH

View full text Add to dashboard Cite

Vogt–Koyanagi–Harada syndrome is a cause of noninfectious panuveitis, leading to significant vision loss in many patients. It is an autoimmune disease occurring in genetically susceptible individuals and clinically presents as bilateral panuveitis with serous retinal detachments and hyperemic, swollen optic discs, which are associated with neurological and auditory manifestations. Early diagnosis and prompt and adequate treatment with immunosuppressive agents (corticosteroids and other immunosuppressive drugs) may halt disease progression and prevent recurrences and vision loss. This review summarizes the current knowledge on the variable clinical aspects of this disease, highlighting diagnostic and treatment strategies.

show abstract

Section: Historical Aspects and Epidemiologymentioning

confidence: 99%

Vogt–Koyanagi–Harada syndrome – current perspectives

Baltmr¹,

Lightman²,

Tomkins-Netzer³

2016

OPTH

View full text Add to dashboard Cite

show abstract

“…Anti-VEGF compounds have shown to be effective against idiopathic choroidal neovascularization (CNV) and CNV secondary to myopia, uveitis, angioid streaks, central serous chorioretinopathy, and punctate inner choroidopathy [6–9]. More specifically, Wu and colleagues [10] successfully treated 2 cases of CNV secondary to VKH with intravitreal injections of bevacizumab. Some additional treatment options that warrant investigation in the management of VKH-associated CNVMs include photodynamic therapy, laser photocoagulation, and combinational pharmacotherapy of anti-VEGF compounds with immunosuppressants.…”

Section: Discussionmentioning

confidence: 99%

The Use of Intravitreal Ranibizumab for Choroidal Neovascularization Associated with Vogt-Koyanagi-Harada Syndrome

Kolomeyer¹,

Roy²,

Chu³

2011

Case Reports in Medicine

View full text Add to dashboard Cite

Purpose. To describe the use of intravitreal ranibizumab for choroidal neovascular membrane (CNVM) secondary to Vogt-Koyanagi-Harada (VKH) syndrome. Methods. Interventional case report. Results. A 50-year-old woman presented with conjunctival injection and bilateral eye pain. Vision was 20/400 and 20/80 in the right and left eyes, respectively. Bilateral iritis, vitritis, and choroidal thickening were evident. Exudative retinal detachment was present in the left eye. Corticosteroid treatment improved vision to 20/40 bilaterally. Methotrexate (MTX) was initiated and vision remained stable for 3 months. After a 5-month loss to follow-up, vision in the left eye decreased to finger counting (CF) and a parafoveal CNVM was identified. After 3 intravitreal ranibizumab injections, vision improved to 20/40. Twelve months later, despite inflammation control, vision decrease to CF due to recurrent CNVM. A fourth ranibizumab injection was given. Twenty months later, best-corrected vision was 20/400, and an inactive CNVM was present in the left eye. Conclusion. After initial CNVM regression and visual acuity improvement due to ranibizumab, the CNVM recurred and became refractory to treatment. Despite control of inflammation and neovascularization, VKH chronicity lead to permanent vision loss in our patient. A combinational treatment approach may be required in such patients.

show abstract

“…A survey ana lysis of 77 patients with PIC reported CNV and subretinal fibrosis in 69% of participants in at least one eye [80]. Other uveitic conditions such as serpiginous choroiditis, VKH and birdshot chorioretinopathy can also be complicated by CNV formation [81][82][83].…”

Section: Reviewmentioning

confidence: 97%

The role of imaging in the diagnosis and management of uveitis

Kim¹

2010

Expert Review of Ophthalmology

View full text Add to dashboard Cite

The purpose of this article is to describe commonly used imaging techniques to diagnose and manage uveitis and its complications. Older imaging techniques, such as fluorescein and indocyanine green angiography, and newer noninvasive techniques, such as optical coherence tomography and fundus autofluorescence, are reviewed. The transition from film-based imaging to digital imaging has been a remarkable achievement and enables easy storage, immediate access, and efficient propagation of information. The recent introduction of spectraldomain optical coherence tomography systems allows axial resolution of retinal tissue approaching that only previously obtainable with histology, but in real time and without the need of tissue biopsy. Fundus autofluorescence offers the potential to further characterize posterior uveitic entities and expand our understanding of underlying disease mechanisms. Continued advances in technology will improve image resolution, speed, and versatility of systems that will translate into increased capability and greater application to diagnose, treat and monitor uveitic conditions. Keywords: B-scan ultrasonography • fluorescein angiography • fundus autofluorescence • fundus photography • imaging • indocyanine green angiography • macular edema • ocular inflammation • optical coherence tomography • uveitis The role of imaging in the diagnosis and management of uveitis Expert Rev. Ophthalmol. 5(5), 699-713 (2010)For reprint orders, please contact reprints@expert-reviews.com Expert Review of Ophthalmology Downloaded from informahealthcare.com by Nyu Medical Center on 02/08/15For personal use only.

show abstract

Intravitreal bevacizumab for choroidal neovascularization secondary to Vogt-Koyanagi-Harada syndrome

Abstract: Intravitreal bevacizumab may be a useful drug to treat CNV in eyes with VKH syndrome.

Cited by 37 publications

References 14 publications

Vogt–Koyanagi–Harada syndrome – current perspectives

Vogt–Koyanagi–Harada syndrome – current perspectives

The Use of Intravitreal Ranibizumab for Choroidal Neovascularization Associated with Vogt-Koyanagi-Harada Syndrome

The role of imaging in the diagnosis and management of uveitis

Contact Info

Product

Resources

About

Intravitreal bevacizumab for choroidal neovascularization secondary to Vogt-Koyanagi-Harada syndrome

Abstract: Intravitreal bevacizumab may be a useful drug to treat CNV in eyes with VKH syndrome.

Cited by 37 publications

References 14 publications

Vogt&ndash;Koyanagi&ndash;Harada syndrome &ndash; current perspectives

Vogt&ndash;Koyanagi&ndash;Harada syndrome &ndash; current perspectives

The Use of Intravitreal Ranibizumab for Choroidal Neovascularization Associated with Vogt-Koyanagi-Harada Syndrome

The role of imaging in the diagnosis and management of uveitis

Contact Info

Product

Resources

About

Vogt–Koyanagi–Harada syndrome – current perspectives

Vogt–Koyanagi–Harada syndrome – current perspectives